West Pharmaceutical Services, Inc. filings document the regulatory record of a Pennsylvania operating company that supplies injectable drug containment, delivery and contract-manufacturing services. Its Form 8-K reports commonly furnish quarterly and full-year operating results, financial presentation materials and Regulation FD disclosures tied to earnings releases.
West's proxy and annual meeting filings cover board elections, executive compensation, advisory votes and shareholder voting results for its common stock. Other current reports record executive-transition matters and related governance disclosures, while exhibit filings provide the formal press releases, presentations and Inline XBRL cover-page data attached to those events.
Janet Brutschea Haugen, a director of West Pharmaceutical Services Inc., received an award of 44 phantom stock units on September 30, 2026. Her reported post-award balance was 350.87 phantom stock units, which are to be settled by delivery of shares upon her termination as a director. A separate entry reports 2,114 shares of common stock held directly.
WEST PHARMACEUTICAL SERVICES INC (WST) reported that Sr. VP & Chief HR Officer Annette F. Favorite exercised employee stock options and sold the resulting common shares in mid-September 2026 under a Rule 10b5-1 trading plan. She exercised options for 7,524 shares at an exercise price of $89.64 per share, then sold 7,524 common shares in three transactions at prices between $345 and $365 per share. The options exercised were part of an award granted on February 20, 2018 that vested annually beginning February 20, 2019.
WEST PHARMACEUTICAL SERVICES INC (WST) reported that Annette F. Favorite, its Sr. VP & Chief HR Officer, exercised employee stock options for 8,135 shares of common stock on September 8, 2026, at exercise prices of $83.47 and $89.64, and sold all 8,135 shares at a weighted average price of $340.81 per share. The options exercised were from awards granted in 2017 and 2018 that vested in four annual installments, and she continues to hold 7,524 option shares from the 2018 grant. No Rule 10b5-1 trading plan is reported.
WEST PHARMACEUTICAL SERVICES INC (WST) reported that its President and CEO, Michel Lagarde, received new equity awards on September 8, 2026. He was granted 37,048 stock options to buy common shares at an exercise price of $337.75 per share, expiring on September 8, 2036. Portions of these option awards vest in four equal annual installments beginning on September 8, 2027, while others cliff vest on September 8, 2031.
Lagarde also received 14,750 restricted stock units, each representing a contingent right to receive one share of WST common stock. Some of these restricted stock units vest annually over four years starting September 8, 2027, and others cliff vest on September 8, 2031. No Rule 10b5-1 trading plan is reported in connection with these awards.
WEST PHARMACEUTICAL SERVICES INC (WST) reported the initial beneficial ownership of its President and CEO, Michel Lagarde, on a Form 3. The filing shows he directly holds 7,850 shares of Common Stock as of August 31, 2026. No purchases, sales, or derivative positions are reported in this filing.
WEST PHARMACEUTICAL SERVICES INC SVP & Chief Financial Officer Robert W. McMahon reported vesting and settlement of restricted stock units on August 11, 2026. He exercised or converted RSUs into 7,149.205 shares of common stock, and 3,109.19 shares of common stock were delivered or withheld at $351.37 per share for payment of exercise price or tax liability. The remaining common shares from these RSU conversions were retained as direct holdings. The Rule 10b5-1 trading plan checkbox was not selected.
FMR LLC has reported beneficial ownership of 3,559,015.80 shares of WEST PHARMACEUTICAL SVCS INC common stock, representing 5.0% of the class as of June 30, 2026. FMR reports sole dispositive power over these shares and no shared voting or dispositive power.
Within FMR’s reporting group, FMR LLC holds 3,469,427.93 shares with sole voting power and 3,559,015.80 shares with sole dispositive power. Abigail P. Johnson is reported as having sole dispositive power over the same 3,559,015.80 shares, but no sole or shared voting power. The filing notes that one or more other persons may receive dividends or sale proceeds from these securities, though no single such person has an interest exceeding five percent of the outstanding common stock.
West Pharmaceutical Services reported strong second-quarter 2026 results, with net sales of $872.3 million, up 13.8%, and organic growth of 12.7%. Diluted EPS was $2.15, up 18.1%, while adjusted-diluted EPS rose 28.8% to $2.37 as gross margin expanded to 37.7% and adjusted operating margin to 22.6%.
Growth was led by the Proprietary Products segment, where net sales increased 16.6% to $722.6 million. High-Value Product Components generated $424.1 million, 49% of total sales, and HVP Delivery Devices $131.2 million, supported by strong Biologics and GLP-1 demand. West Vantage net sales were $149.7 million, up 2.0%, though margins were pressured by a cybersecurity incident.
For the first half of 2026, operating cash flow was $213.9 million, capital expenditures $85.9 million, and free cash flow $128.0 million. The company repurchased 1.8 million shares for $454.3 million and declared a quarterly dividend of $0.22 per share. Full-year 2026 guidance was raised to net sales of $3.345–$3.380 billion and adjusted-diluted EPS of $8.85–$9.05, with Q3 2026 net sales expected at $820–$835 million and adjusted-diluted EPS of $2.14–$2.24.
West Pharmaceutical Services, Inc. entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd., effective July 14, 2026. The company holds a 49% ownership interest in Daikyo.
The Crosslicense Agreement provides mutual sharing of know-how and cooperation in developing closures, vials, cartridges, syringes and related pharmaceutical packaging and delivery components. Each party may license the other’s know-how, patents and trademarks; Daikyo’s license from West is non-exclusive, while West’s license from Daikyo is exclusive outside Japan, in each case subject to limited exceptions. The arrangement is royalty-free except for a fixed royalty rate on certain patents and non-patented technical information. One Distributorship Agreement grants West exclusive rights to distribute Daikyo products outside Japan, and the other grants Daikyo non-exclusive rights to distribute West products in Japan. Each agreement has a 10-year term and may be terminated earlier under specified circumstances, including mutual consent or a change in control.